MAPT and supranuclear palsy, progressive, 1: Oliveira Hauer et al. have explored the utility of tau PET tracer 18F-RO948 uptake in the GPi alongside structural MRI and CSF NfL levels and found that combining these three biomarkers enhanced accuracy (AUC > 0.90) in distinguishing PSP from both controls and alpha-synucleinopathies (PD, Lewy body dementia) [106].